These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 18565245)

  • 21. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab.
    Brandt J; Haibel H; Cornely D; Golder W; Gonzalez J; Reddig J; Thriene W; Sieper J; Braun J
    Arthritis Rheum; 2000 Jun; 43(6):1346-52. PubMed ID: 10857793
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictive factors for partial remission according to the Ankylosing Spondylitis Assessment Study working group in patients with ankylosing spondylitis treated with anti-TNFα drugs.
    Perrotta FM; Addimanda O; Ramonda R; D'Angelo S; Lubrano E; Marchesoni A; Olivieri I; Punzi L; Salvarani C; Spadaro A
    Reumatismo; 2014 Nov; 66(3):208-14. PubMed ID: 25376955
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and Efficacy of Intravenous Golimumab in Adults with Ankylosing Spondylitis: Results through 1 Year of the GO-ALIVE Study.
    Reveille JD; Deodhar A; Caldron PH; Dudek A; Harrison DD; Kim L; Lo KH; Leu JH; Hsia EC
    J Rheumatol; 2019 Oct; 46(10):1277-1283. PubMed ID: 30824635
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increased efficacy of infliximab associated with methotrexate in ankylosing spondylitis.
    Pérez-Guijo VC; Cravo AR; Castro Mdel C; Font P; Muñoz-Gomariz E; Collantes-Estevez E
    Joint Bone Spine; 2007 May; 74(3):254-8. PubMed ID: 17387031
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of age, sex, physical function, health-related quality of life, and treatment with adalimumab on work status and work productivity of patients with ankylosing spondylitis.
    Maksymowych WP; Gooch KL; Wong RL; Kupper H; van der Heijde D
    J Rheumatol; 2010 Feb; 37(2):385-92. PubMed ID: 19955052
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Health-related quality of life outcomes in patients with active ankylosing spondylitis treated with adalimumab: results from a randomized controlled study.
    Davis JC; Revicki D; van der Heijde DM; Rentz AM; Wong RL; Kupper H; Luo MP
    Arthritis Rheum; 2007 Aug; 57(6):1050-7. PubMed ID: 17665483
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis.
    Brandt J; Listing J; Haibel H; Sörensen H; Schwebig A; Rudwaleit M; Sieper J; Braun J
    Rheumatology (Oxford); 2005 Mar; 44(3):342-8. PubMed ID: 15561737
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Maintained clinical response of infliximab treatment in ankylosing spondylitis: a 6-year long-term study.
    Saougou I; Markatseli TE; Voulgari PV; Drosos AA
    Joint Bone Spine; 2010 Jul; 77(4):325-9. PubMed ID: 20452801
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of infliximab in refractory ankylosing spondylitis: results of a six-month open-label study.
    Breban M; Vignon E; Claudepierre P; Devauchelle V; Wendling D; Lespessailles E; Euller-Ziegler L; Sibilia J; Perdriger A; Mezières M; Alexandre C; Dougados M
    Rheumatology (Oxford); 2002 Nov; 41(11):1280-5. PubMed ID: 12422001
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years--early clinical response predicts long-term outcome.
    Baraliakos X; Listing J; Fritz C; Haibel H; Alten R; Burmester GR; Krause A; Schewe S; Schneider M; Sörensen H; Schmidt R; Sieper J; Braun J
    Rheumatology (Oxford); 2011 Sep; 50(9):1690-9. PubMed ID: 21672969
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relationship of work disability between the disease activity, depression and quality of life in patients with ankylosing spondylitis.
    Sağ S; Nas K; Sağ MS; Tekeoğlu İ; Kamanlı A
    J Back Musculoskelet Rehabil; 2018; 31(3):499-505. PubMed ID: 29504521
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1.
    Sieper J; Lenaerts J; Wollenhaupt J; Rudwaleit M; Mazurov VI; Myasoutova L; Park S; Song Y; Yao R; Chitkara D; Vastesaeger N;
    Ann Rheum Dis; 2014 Jan; 73(1):101-7. PubMed ID: 23696633
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and efficacy of readministration of infliximab after longterm continuous therapy and withdrawal in patients with ankylosing spondylitis.
    Baraliakos X; Listing J; Rudwaleit M; Brandt J; Alten R; Burmester G; Gromnica-Ihle E; Haibel H; Schewe S; Schneider M; Sörensen H; Zeidler H; Visvanathan S; Sieper J; Braun J
    J Rheumatol; 2007 Mar; 34(3):510-5. PubMed ID: 17299842
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis.
    Brandt J; Khariouzov A; Listing J; Haibel H; Sörensen H; Grassnickel L; Rudwaleit M; Sieper J; Braun J
    Arthritis Rheum; 2003 Jun; 48(6):1667-75. PubMed ID: 12794835
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Infliximab therapy in patients with ankylosing spondylitis: an open label 12 month study.
    Temekonidis TI; Alamanos Y; Nikas SN; Bougias DV; Georgiadis AN; Voulgari PV; Drosos AA
    Ann Rheum Dis; 2003 Dec; 62(12):1218-20. PubMed ID: 14644863
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low-dose infliximab treatment for ankylosing spondylitis--clinically- and cost-effective.
    Jois RN; Leeder J; Gibb A; Gaffney K; Macgregor A; Somerville M; Scott DG
    Rheumatology (Oxford); 2006 Dec; 45(12):1566-9. PubMed ID: 16705043
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High intraindividual week-to-week variability in BASDAI and BASFI values: are several evaluations needed before starting or stopping TNFalpha antagonist therapy for spondyloarthropathies?
    Berthelot JM; Tortellier L; Lavy-Bregeon D; Le Goff B; Maugars Y
    Joint Bone Spine; 2008 Mar; 75(2):167-71. PubMed ID: 18296097
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical and imaging correlates of response to treatment with infliximab in patients with ankylosing spondylitis.
    Stone M; Salonen D; Lax M; Payne U; Lapp V; Inman R
    J Rheumatol; 2001 Jul; 28(7):1605-14. PubMed ID: 11469469
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Infliximab improves productivity and reduces workday loss in patients with ankylosing spondylitis: results from a randomized, placebo-controlled trial.
    van der Heijde D; Han C; DeVlam K; Burmester G; van den Bosch F; Williamson P; Bala M; Han J; Braun J
    Arthritis Rheum; 2006 Aug; 55(4):569-74. PubMed ID: 16874778
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Maintenance of improvement in spinal mobility, physical function and quality of life in patients with ankylosing spondylitis after 5 years in a clinical trial of adalimumab.
    van der Heijde D; Breban M; Halter D; DiVittorio G; Bratt J; Cantini F; Kary S; Pangan AL; Kupper H; Rathmann SS; Sieper J; Mease PJ
    Rheumatology (Oxford); 2015 Jul; 54(7):1210-9. PubMed ID: 25541333
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.